Open AccessEvaluate the Therapeutic Effect of Allicin (L-cysteine) on Clinical Presentation and Prognosis in Patients with COVID-19
Author(s) -
Hosein Yaghoubian,
Hossein Niktale,
Arash Peivandi Yazdi,
Vahideh Ghorani,
Masoud Mahdavi Rashed,
Amir Masoud Hashemian
Publication year - 2021
Publication title -
european journal of translational myology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.271
H-Index - 6
eISSN - 2037-7460
pISSN - 2037-7452
DOI - 10.4081/ejtm.2021.9518
Subject(s) - allicin , medicine , placebo , therapeutic effect , cysteine , clinical trial , gastroenterology , pharmacology , pathology , chemistry , biochemistry , alternative medicine , enzyme
The antiviral effectiveness of allicin (L-cysteine) has been shown by numerous studies in both levels of clinical and animals. The aim of this study was to evaluate the therapeutic effect of allicin (L-cysteine) on clinical presentation and prognosis. In the current study, 66 patients with COVID-19 based on clinical, radiological presentations and RT-PCR results, were enrolled in two groups of placebo and allicin. In the both allicin (L-cysteine) and placebo groups (n=33 in each group), the capsules were prescribed two times a day for two weeks. Clinical signs and symptoms, blood parameters and chest CT scan were evaluated before and two weeks after treatment. The results showed that allicin (L-cysteine) could significantly impact on improvement of signs and symptoms of COVID-19 after two weeks of treatment in comparison to placebo. Allicin (L-cysteine) not only improve the clinical signs, but also ameliorate the lab and radiological data, which suggest a therapeutic effect for this agent in COVID-19. Our data suggest the therapeutic effect of allicin (L-cysteine) on COVID-19 through improvement of clinical symptoms and acceleration of the healing process.